Cargando…

Detection of infections with hepatitis B virus, hepatitis C virus, and human immunodeficiency virus by analyses of dried blood spots - performance characteristics of the ARCHITECT system and two commercial assays for nucleic acid amplification

BACKGROUND: Nowadays, dried blood spots (DBS) are primarily used to obtain diagnostic access to risk collectives such as intravenous drug users, who are prone to infections with hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). Before DBS analyses can be used...

Descripción completa

Detalles Bibliográficos
Autores principales: Ross, R Stefan, Stambouli, Oumaima, Grüner, Nico, Marcus, Ulrich, Cai, Wei, Zhang, Weidong, Zimmermann, Ruth, Roggendorf, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3599381/
https://www.ncbi.nlm.nih.gov/pubmed/23497102
http://dx.doi.org/10.1186/1743-422X-10-72
_version_ 1782262950533267456
author Ross, R Stefan
Stambouli, Oumaima
Grüner, Nico
Marcus, Ulrich
Cai, Wei
Zhang, Weidong
Zimmermann, Ruth
Roggendorf, Michael
author_facet Ross, R Stefan
Stambouli, Oumaima
Grüner, Nico
Marcus, Ulrich
Cai, Wei
Zhang, Weidong
Zimmermann, Ruth
Roggendorf, Michael
author_sort Ross, R Stefan
collection PubMed
description BACKGROUND: Nowadays, dried blood spots (DBS) are primarily used to obtain diagnostic access to risk collectives such as intravenous drug users, who are prone to infections with hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). Before DBS analyses can be used in this diagnostic context, however, a comprehensive evaluation of its performance characteristics must be conducted. To the best of our knowledge, the current study presents for the first time such essential data for the Abbott ARCHITECT system, which is currently the worldwide leading platform in this field of infection diagnostics. METHODS: The investigation comprised 1,762 paired serum/DBS samples and a total of 3,524 determinations with the Abbott ARCHITECT HBsAg, anti-HBc, anti-HBs, anti-HCV and HIV-1-p24-antigen/anti-HIV 1/2 assays as well as with the artus HBV LC PCR and VERSANT HCV RNA qualitative (TMA) tests. RESULTS: In the context of DBS testing, a specificity of 100% was recorded for the seven serological and molecular biological assays. The analytical sensitivity of HBsAg, anti-HBc, anti-HBs, anti-HCV, HIV-1-p24-antigen/anti-HIV 1/2, HBV DNA, and HCV RNA detections in DBS eluates was 98.6%, 97.1%, 97.5%, 97.8%, 100%, 93%, and 100%, respectively. DISCUSSION/CONCLUSIONS: The results obtained indicate that it is today possible to reliably detect HBsAg, anti-HBc, anti-HBs, anti-HCV and HIV-1-p24 antigen/anti-HIV 1/2 with state-of-the-art analytical systems such as the Abbott ARCHITECT in DBS eluates even when a comparatively high elution volume of 1,000 μl is used. They also provide evidence for the inherent analytical limits of DBS testing, which primarily concern the anti-HBc/anti-HBs system for individuals with HIV infections and nucleic acid tests with relatively low analytical sensitivity.
format Online
Article
Text
id pubmed-3599381
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35993812013-03-17 Detection of infections with hepatitis B virus, hepatitis C virus, and human immunodeficiency virus by analyses of dried blood spots - performance characteristics of the ARCHITECT system and two commercial assays for nucleic acid amplification Ross, R Stefan Stambouli, Oumaima Grüner, Nico Marcus, Ulrich Cai, Wei Zhang, Weidong Zimmermann, Ruth Roggendorf, Michael Virol J Research BACKGROUND: Nowadays, dried blood spots (DBS) are primarily used to obtain diagnostic access to risk collectives such as intravenous drug users, who are prone to infections with hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). Before DBS analyses can be used in this diagnostic context, however, a comprehensive evaluation of its performance characteristics must be conducted. To the best of our knowledge, the current study presents for the first time such essential data for the Abbott ARCHITECT system, which is currently the worldwide leading platform in this field of infection diagnostics. METHODS: The investigation comprised 1,762 paired serum/DBS samples and a total of 3,524 determinations with the Abbott ARCHITECT HBsAg, anti-HBc, anti-HBs, anti-HCV and HIV-1-p24-antigen/anti-HIV 1/2 assays as well as with the artus HBV LC PCR and VERSANT HCV RNA qualitative (TMA) tests. RESULTS: In the context of DBS testing, a specificity of 100% was recorded for the seven serological and molecular biological assays. The analytical sensitivity of HBsAg, anti-HBc, anti-HBs, anti-HCV, HIV-1-p24-antigen/anti-HIV 1/2, HBV DNA, and HCV RNA detections in DBS eluates was 98.6%, 97.1%, 97.5%, 97.8%, 100%, 93%, and 100%, respectively. DISCUSSION/CONCLUSIONS: The results obtained indicate that it is today possible to reliably detect HBsAg, anti-HBc, anti-HBs, anti-HCV and HIV-1-p24 antigen/anti-HIV 1/2 with state-of-the-art analytical systems such as the Abbott ARCHITECT in DBS eluates even when a comparatively high elution volume of 1,000 μl is used. They also provide evidence for the inherent analytical limits of DBS testing, which primarily concern the anti-HBc/anti-HBs system for individuals with HIV infections and nucleic acid tests with relatively low analytical sensitivity. BioMed Central 2013-03-05 /pmc/articles/PMC3599381/ /pubmed/23497102 http://dx.doi.org/10.1186/1743-422X-10-72 Text en Copyright ©2013 Ross et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Ross, R Stefan
Stambouli, Oumaima
Grüner, Nico
Marcus, Ulrich
Cai, Wei
Zhang, Weidong
Zimmermann, Ruth
Roggendorf, Michael
Detection of infections with hepatitis B virus, hepatitis C virus, and human immunodeficiency virus by analyses of dried blood spots - performance characteristics of the ARCHITECT system and two commercial assays for nucleic acid amplification
title Detection of infections with hepatitis B virus, hepatitis C virus, and human immunodeficiency virus by analyses of dried blood spots - performance characteristics of the ARCHITECT system and two commercial assays for nucleic acid amplification
title_full Detection of infections with hepatitis B virus, hepatitis C virus, and human immunodeficiency virus by analyses of dried blood spots - performance characteristics of the ARCHITECT system and two commercial assays for nucleic acid amplification
title_fullStr Detection of infections with hepatitis B virus, hepatitis C virus, and human immunodeficiency virus by analyses of dried blood spots - performance characteristics of the ARCHITECT system and two commercial assays for nucleic acid amplification
title_full_unstemmed Detection of infections with hepatitis B virus, hepatitis C virus, and human immunodeficiency virus by analyses of dried blood spots - performance characteristics of the ARCHITECT system and two commercial assays for nucleic acid amplification
title_short Detection of infections with hepatitis B virus, hepatitis C virus, and human immunodeficiency virus by analyses of dried blood spots - performance characteristics of the ARCHITECT system and two commercial assays for nucleic acid amplification
title_sort detection of infections with hepatitis b virus, hepatitis c virus, and human immunodeficiency virus by analyses of dried blood spots - performance characteristics of the architect system and two commercial assays for nucleic acid amplification
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3599381/
https://www.ncbi.nlm.nih.gov/pubmed/23497102
http://dx.doi.org/10.1186/1743-422X-10-72
work_keys_str_mv AT rossrstefan detectionofinfectionswithhepatitisbvirushepatitiscvirusandhumanimmunodeficiencyvirusbyanalysesofdriedbloodspotsperformancecharacteristicsofthearchitectsystemandtwocommercialassaysfornucleicacidamplification
AT stamboulioumaima detectionofinfectionswithhepatitisbvirushepatitiscvirusandhumanimmunodeficiencyvirusbyanalysesofdriedbloodspotsperformancecharacteristicsofthearchitectsystemandtwocommercialassaysfornucleicacidamplification
AT grunernico detectionofinfectionswithhepatitisbvirushepatitiscvirusandhumanimmunodeficiencyvirusbyanalysesofdriedbloodspotsperformancecharacteristicsofthearchitectsystemandtwocommercialassaysfornucleicacidamplification
AT marcusulrich detectionofinfectionswithhepatitisbvirushepatitiscvirusandhumanimmunodeficiencyvirusbyanalysesofdriedbloodspotsperformancecharacteristicsofthearchitectsystemandtwocommercialassaysfornucleicacidamplification
AT caiwei detectionofinfectionswithhepatitisbvirushepatitiscvirusandhumanimmunodeficiencyvirusbyanalysesofdriedbloodspotsperformancecharacteristicsofthearchitectsystemandtwocommercialassaysfornucleicacidamplification
AT zhangweidong detectionofinfectionswithhepatitisbvirushepatitiscvirusandhumanimmunodeficiencyvirusbyanalysesofdriedbloodspotsperformancecharacteristicsofthearchitectsystemandtwocommercialassaysfornucleicacidamplification
AT zimmermannruth detectionofinfectionswithhepatitisbvirushepatitiscvirusandhumanimmunodeficiencyvirusbyanalysesofdriedbloodspotsperformancecharacteristicsofthearchitectsystemandtwocommercialassaysfornucleicacidamplification
AT roggendorfmichael detectionofinfectionswithhepatitisbvirushepatitiscvirusandhumanimmunodeficiencyvirusbyanalysesofdriedbloodspotsperformancecharacteristicsofthearchitectsystemandtwocommercialassaysfornucleicacidamplification